1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow bemarituzumab, irinotecan: new trials by email Literature Review of bemarituzumab, irinotecan trials Research Report on bemarituzumab, irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil - Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 126 | 2025-03-03 | 2026-01-07 |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
Germany (1)
Salah Eddin Al-Batran, Prof. Dr. (1) · Sylvie Lorenzen, Prof. Dr. (1)